Osteoporosis and other extraintestinal symptoms and complications of inflammatory bowel diseases

Digestive Diseases

Volumn 21, Issue 2, 2003, Pages 138-145

  Reinshagen, Max ^a   Von Tirpitz, Christian ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Crohn's disease; Inflammatory bowel disease; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; FLUORIDE SODIUM; HORMONE; IBANDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; CHOLANGITIS; CHOLELITHIASIS; CLINICAL FEATURE; CLINICAL TRIAL; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; GALLSTONE; HUMAN; IRIDOCYCLITIS; NEPHROLITHIASIS; OSTEOPOROSIS; PANCREATITIS; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; ULTRASOUND; WORLD HEALTH ORGANIZATION;

ARTHRALGIA; ARTHRITIS; CHOLANGITIS; ERYTHEMA NODOSUM; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY CALCULI; OSTEOPOROSIS; PYODERMA GANGRENOSUM; SPONDYLITIS, ANKYLOSING; THROMBOEMBOLISM;

EID: 0142218860     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073245     Document Type: Review

References (61)

1. Greenstein AJ, Janowitz HD, Sachar DB: The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine 1976;5:401-412.
2. Diamond T, Stiel D, Posen S: Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989;110:430-436.
3. Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C: High prevalence of vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-658.
4. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis (see comments). J Bone Miner Res 1994;9:1137-1141.
5. von Tirpitz C, Klaus J, Steinkamp M, Mason RA, Kratzer W, Adler G, Rieber A, Reinshagen M: Quantitative ultrasound of the proximal phalanges and dual energy x-ray absorptiometry in Crohn's disease patients with osteopenia. J Gastroenterol 2003;38:238-243.
6. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A: Calcaneal ultrasound bone densitometry in inflammatory bowel disease: A comparison with double X-ray densitometry of the lumbar spine. Am J Gastroenterol 1998;93:2339-2344.
7. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK: A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-76.
8. von Tirpitz C, Pischulti G, Klaus J, Rieber A, Bruckel J, Bohm BO, Adler G, Reinshagen M: Pathological bone density in chronic inflammatory bowel diseases: Prevalence and risk factors. Z Gastroenterol 1999;37:5-12.
9. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE: A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
10. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A: 1995: Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol. Hepatol 1993;7:609-614.
11. Schulte C, Dignass AU, Mann K, Goebell H: Bone loss in patients with inflammatory bowel disease is less than expected: A follow-up study. Scand J Gastroenterol 1999;34:696-702.
12. Ghosh S, Cowen S, Hannan WJ, Ferguson A: Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-1039.
13. von Tirpitz C, Steder-Neukamm U, Glas K, Adler G, Reinshagen M: Osteoporosis in inflammatory bowel disease: Results of a survey with members of the German Crohn's and Colitis association. Z Gastroenterol, 2003;in press.
14. Clements D, Compston JE, Evans WD, Rhodes J: Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-1546.
15. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
16. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD: Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002;288:872-881.
17. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F: A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid- using patients with inflammatory bowel disease: A pilot study. Aliment Pharmacol Ther 1996;10:777-786.
18. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason RA, Boehm BO, Adler G, Reinshagen M: Therapy of osteoporosis in patients with Crohn's disease: A randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003;17:807-816.
19. Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S: Osteoporosis in inflammatory bowel disease: Effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002;16:919-927.
20. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, et al: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study. Osteoporos Int 1998;8:4-12.
21. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-809.
22. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
23. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs R-WJ, Dequeker J, Favus M: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443.
24. Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-646.
25. Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF: Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial. Gastroenterology 1998;115:36-41.
26. Salmi M, Jalkanen S: Human leukocyte sub-populations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol 2001;166:4650-4657.
27. May E, Marker-Hermann E, Wittig BM, Zeitz M, Meyer-zum-Buschenfelde KH, Duchmann R: Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000;119:1745-1755.
28. Orchard TR: Arthritis associated with inflammatory bowel disease; in Bayless TM, Hanauer SB (eds): Advanced Therapy of Inflammatory Bowel Disease. Decker, Hamilton, London, 2001, pp 279-288.
29. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history. Gut 1998;42:387-391.
30. Florin TH, Graffner H, Nilsson LG, Persson T: Treatment of joint pain in Crohn's patients with budesonide controlled ileal release. Clin Exp Pharmacol Physiol 2000;27:295-298.
31. Adler G, Reinshagen M: Extraintestinale Manifestationen. Z Gastroenterol 2003;41:54-61.
32. Sieper J, Braun J: New treatment options in ankylosing spondylitis: A role for anti-TNFα therapy. Ann Rheum Dis 2001;60(suppl 3):iii58-iii61.
33. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-1847.
34. Bonner GF, Walczak M, Kitchen L, Bayona M: Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:1946-1948.
35. Dominitz JA, Koepsell TD, Boyko EJ: Association between analgesic use and inflammatory bowel disease flares (abstract). Gastroenterology 2000;118:A581.
36. Mahadevan U, Loftus EVJ, Tremaine WJ, Sandborn WJ: Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002;97:910-914.
37. Nousari HC, Provost TT, Anhalt GJ: Cutaneous manifestations of inflammatory bowel disease; in Bayless TM, Hanauer SB (eds): Advanced Therapy of Inflammatory Bowel Disease. London, B.C. Becker, Hamilton, 2001, pp 271-274.
38. Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, Griga T: Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001;39:137-144.
39. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7.
40. Petering H, Kiehl P, Breuer C, Kapp A, Werfel T: Pyoderma gangraenosum: Erfolgreiche topische Therapie mit Tacrolimus (FK506). [Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506)]. Hautarzt 2001;52:47-50.
41. Kimble RM, Tickler AK, Nicholls VS, Cleghorn G: Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J Pediatr Gastroenterol Nutr 2002;34:555-557.
42. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001;137:930-933.
43. Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000;284:1546-1548.
44. Kanekura T, Maruyama I, Kanzaki T: Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002;47:320-321.
45. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 2001;96:1116-1122.
46. Latkany PA, Jabs DA: Ocular manifestations of inflammatory bowel disease; in Bayless TM, Hanauer SB (eds): Advanced Therapy of Inflammatory Bowel Disease. London, Decker, 2001, pp 275-277.
47. Raj V, Lichtenstein DR: Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clins N Am 1999;28:491-513.
48. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, et al: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 2000;31:7-11.
49. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
50. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: Outcome after endoscopic treatment. J Hepatol 2002;36:151-156.
51. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L: Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis: An 8-year prospective study. J Hepatol 1997;26:560-566.
52. Stiehl A, Benz C, Sauer P: Primary sclerosing cholangitis. Can J Gastroenterol 2000;14:311-315.
53. Wiesner RH: Liver transplantation for primary sclerosing cholangitis: Timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 2001;15:667-680.
54. Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, Abu-Elmagd KM: Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002;35:380-384.
55. Buno-Soto A, Torres-Jimenez R, Olveira A, Fernandez-Blanco-Herraiz I, Montero-Garcia A, Mateos-Anton F: Lithogenic risk factors for renal stones in patients with Crohn's disease. Arch Esp Urol 2001;54:282-292.
56. Ettinger B, Citron JT, Livermore B, Dolman LI: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679-684.
57. Lapidus A, Bangstad M, Astrom M, Muhrbeck O: The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999;94:1261-1266.
58. Brink MA, Slors JF, Keulemans YC, Mok KS, De Waart DR, Carey MC, Groen AK, Tytgat GN: Enterohepatic cycling of bilirubin: A putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastro 1999;116:1420-1427.
59. Bernstein CN, Blanchard JF, Houston DS, Wajda A: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001;85:430-434.
60. Koutroubakis IE: Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis 2000;18:161-167.
61. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F: Thrombosis in inflammatory bowel disease: Clinical setting, procoagulant profile and factor V Leiden. QJM 1997;90:183-188.